Near Real-Time Osteoporosis and Bone Cancer Test Developed
|
By LabMedica International staff writers Posted on 30 Aug 2015 |

Image: Photomicrograph demonstrating typical multiple myeloma histology, with monoclonal proliferation of plasma cells (Photo courtesy of Ohio State University College of Medicine).
A new test which measures changes in calcium isotope ratios offers the possibility of near real time monitoring of bone diseases, such as osteoporosis and multiple myeloma.
Bones are largely built of calcium, and the turnover of calcium can indicate the development of bone diseases such as osteoporosis and the cancer multiple myeloma and using techniques developed by geochemists it was found possible to apply them to a new, rapid test of bone health.
Scientists at Arizona State University (Tempe, AZ, USA) worked with the US National Aeronautics and Space Administration (NASA, Washington DC, USA) and measured calcium isotope ratios in urine from 30 shuttle astronauts, before, during, and after the flights. This allowed them to confirm that the test worked at high sensitivity. They also looked at a group of 71 patients who either had multiple myeloma (bone cancer), or were at risk of multiple myeloma.
The methodology used mass spectrometry and can discern the relative ratios of the calcium isotopes 42Ca and 44Ca in bone. The researchers found that lighter calcium isotopes, such as 42Ca, are absorbed from the blood into the bone during bone formation. Conversely, these light isotopes tend to be released into the bloodstream when bones break down. By measuring the ratios of the two isotopes in blood or urine scientists can calculate the rate of change of bone mass.
Ariel Anbar, PhD, the lead scientists of the study said, “What we saw with cancer patients was interesting. Those patients who tended to lose the lighter 42Ca isotope seemed to be the ones where the cancer was the most active. This means that the tests could theoretically feed into decisions on whether or not to treat a patient, for example if a cancer was dormant or growing very slowly, and to assess the effectiveness of treatments. The advantage for this methodology is that the patient doesn't have to come to the machine; the measurements can be done with a blood or urine test.”
Related Links:
Arizona State University
US National Aeronautics and Space Administration
Bones are largely built of calcium, and the turnover of calcium can indicate the development of bone diseases such as osteoporosis and the cancer multiple myeloma and using techniques developed by geochemists it was found possible to apply them to a new, rapid test of bone health.
Scientists at Arizona State University (Tempe, AZ, USA) worked with the US National Aeronautics and Space Administration (NASA, Washington DC, USA) and measured calcium isotope ratios in urine from 30 shuttle astronauts, before, during, and after the flights. This allowed them to confirm that the test worked at high sensitivity. They also looked at a group of 71 patients who either had multiple myeloma (bone cancer), or were at risk of multiple myeloma.
The methodology used mass spectrometry and can discern the relative ratios of the calcium isotopes 42Ca and 44Ca in bone. The researchers found that lighter calcium isotopes, such as 42Ca, are absorbed from the blood into the bone during bone formation. Conversely, these light isotopes tend to be released into the bloodstream when bones break down. By measuring the ratios of the two isotopes in blood or urine scientists can calculate the rate of change of bone mass.
Ariel Anbar, PhD, the lead scientists of the study said, “What we saw with cancer patients was interesting. Those patients who tended to lose the lighter 42Ca isotope seemed to be the ones where the cancer was the most active. This means that the tests could theoretically feed into decisions on whether or not to treat a patient, for example if a cancer was dormant or growing very slowly, and to assess the effectiveness of treatments. The advantage for this methodology is that the patient doesn't have to come to the machine; the measurements can be done with a blood or urine test.”
Related Links:
Arizona State University
US National Aeronautics and Space Administration
Latest Pathology News
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
- Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
- Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
- Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
- AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
- AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
- Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
- New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
- AI-Powered Tool to Transform Dermatopathology Workflow
- AI Tool Predicts Chemotherapy Response from Biopsy Slides
- Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Channels
Molecular Diagnostics
view channel
Cancer-Related Mutations in Immune Cells Linked to Alzheimer’s
Alzheimer’s disease is marked by protein aggregation and inflammatory changes in the brain’s immune system, yet its molecular drivers remain incompletely understood. With aging, human cells accumulate... Read more
Composite Blood Biomarkers Enable Early Detection of Common Cancers
Early diagnosis of colorectal, lung, and ovarian cancers remains challenging, with many patients identified only after tumors have begun to spread. A scalable blood test could expand access to screening,... Read more
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read moreHematology
view channel
Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Label-Free Microscopy Methodd Enables Faster, Quantitative Detection of Malaria
Microscopy of blood smears remains a cornerstone for malaria diagnosis but can be slow, stain-dependent, and operator intensive. With more than 200 million infections and over 600,000 deaths annually,... Read more
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
Prostate and breast cancers are among the most commonly diagnosed malignancies worldwide, and heterogeneous disease biology complicates risk stratification and treatment selection. Clinicians increasingly... Read more
AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
Clinicians face persistent challenges identifying which patients with metastatic non-small cell lung cancer will benefit from immunotherapy, even as these agents transform oncology care.... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more







